OABI: Pangali EV/EBITDA OmniAb Corp

Simbol lan logo merek OmniAb (OABI)

OmniAb, Inc. (OABI) provides antibody discovery technologies via transgenic animals for major B2B partners, targeting the biotech development market. This chart shows the EV/EBITDA market valuation is 0.00. OmniAb, Inc. (OABI) monetizes its unique screening and database through licenses and royalties. Stable demand for pharmaceuticals makes the business a defensive asset that functions independently of global economic fluctuations.

OABI OmniAb Inc: Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 15.11.2026

Rincian analitis perusahaan OmniAb, Inc.

- rega saham lan target rega konsensus:
Analisis wiwitan perusahaan:OABI (omniab.com)
Produk asli OmniAb

OmniAb, Inc. (OABI) utilizes AI platforms to accelerate antibody discovery, a process that requires significant capital expenditures. The company's current EV/EBITDA value illustrates the enterprise value, including debt, relative to operating profit. This metric determines the payback period for all assets, excluding the impact of taxes and depreciation. A decline in this ratio signals that the asset is undervalued, while a sharp increase warns of overheating quotes.